country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P10445

Copy Link Print Information

TAT-PiET

TAT-PiET is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4. TAT-PiET can reduce BRD4 and JMJD6 levels and inhibit cell proliferation. TAT-PiET also resists the endocrine resistance of ERα-positive breast cancer cells. TAT-PiET can be used for the research of cancer, such as breast cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 3036046-03-1
Formel: C₁₁₀H₁₉₂N₄₈O₂₇S
Molecular Weight:2651.07

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

TAT-PiET Chemical Structure

CAS. Nr.: 3036046-03-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

BRD4

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen :

In Vitro

TAT-PiET inhibits proliferation in MCF7, T47D, MDA-MB231, and BT549 cell with EC₅₀ values of 8.13, 13.35, 4.68 and 32.34 μM^[1].
TAT-PiET (10 μM) inhibits colony formations in MCF7 and MDA-MB231 cells TAT-PiET (10 μM) inhibits migration in MCF7 and MDA-MB231 cells TAT-PiET (10 μM, 6 h) decreases expression of c-Myc, N-myc, and CCND1 in MCF7 and MDA-MB-231 cells TAT-PiET (10 μM) increases sensitivities in Tamoxifen (HY-13757A) -resistant MCF7 and T47Dcells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

MCF7 and MDA-MB-231 cells
Concentration:

10 μM
Incubation Time:

6 h
Result:

Decreased expression of c-Myc, N-myc, and CCND1.

In Vivo

TAT-PiET (25 mg/kg, i.p., every 2 days) inhibits tumor growth in MCF/MDA-MB2317 tumor mice models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

MCF7/MDA-MB231 tumor mice models^[1]
Dosage:

25 mg/kg
Administration:

Intraperitoneally injection, every 2 days
Result:

Reduced tumor volume and weight.
Reduced BRD4 and JMJD6 levels.
Reduced c-Myc, N-myc, and CCND1 levels.

Chemical Information

CAS. Nr. 3036046-03-1
Molecular Weight 2651.07
Formel C₁₁₀H₁₉₂N₄₈O₂₇S
Sequence

Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Arg-Asn-Gln-Lys-Phe-Lys-Cys-Gly-Glu
Sequence Shortening

YGRKKRRQRRRRNQKFKCGE
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (262 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Huang QX, et al. Peptide Inhibitor Targeting the Extraterminal Domain in BRD4 Potently Suppresses Breast Cancer Both In Vitro and In Vivo. J Med Chem. 2024 Apr 25;67(8):6658-6672. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Angebot einholen Auf Lager